We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
KADCYLA (Roche Products Pty Ltd)
Product name
KADCYLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
105 working days (255)
Active ingredients
trastuzumab emtansine (rch)
Registration type
EOI
Indication
Early breast cancer
KADCYLA (powder for injection), as a single agent, is now also indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
Registration process
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available